Equities

Haw Par Corporation Ltd

Haw Par Corporation Ltd

Actions
  • Price (USD)8.35
  • Today's Change0.00 / 0.00%
  • Shares traded900.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 04 2024 15:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Haw Par Corporation Limited is a Singapore-based holding company. The principal activities of the Company are licensing the Tiger trademarks and owning and holding investments for the long-term. Its segments include Healthcare products, Investments and Others. Its Healthcare products segment is engaged in manufacturing and distributing topical analgesic products under the Tiger Balm and Kwan Loong brands. Its Investments segment is engaged in long term investing activities, mainly in quoted securities in Asia. Its Others segment includes the property division, which owns and leases out several investment properties in Asia, and the leisure division, which provides family and tourist-oriented leisure activities in the form of oceanariums. Its Tiger Balm brand offers products such as Tiger Balm White Ointment, Tiger Balm Muscle Rub, Tiger Balm Back Pain Patch, and Tiger Balm Muscle Rub. Its Kwan Loong brand offers products such as Kwan Loong Medicated Oil and Kwan Loong Refresher.

  • Revenue in SGD (TTM)239.06m
  • Net income in SGD234.43m
  • Incorporated1969
  • Employees595.00
  • Location
    Haw Par Corporation Ltd401 Commonwealth Drive#03-03 Haw Par Techno Centre 149598SingaporeSGP
  • Phone+65 63379102
  • Fax+65 63369232
  • Websitehttps://www.hawpar.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.